Anxiety/Depression, Sleep and Alcohol in Elderly Anxiety/Depression, Sleep Disturbances and Alcohol Use Disorder in Elderly With Cognitive Complaints (MEM-ASA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04368416|
Recruitment Status : Not yet recruiting
First Posted : April 29, 2020
Last Update Posted : July 20, 2020
The goal of MEM-ASA is to investigate the prevalence of anxiety/depression, sleep disturbances and alcohol use disorder in elderly with cognitive complaints.
In memory clinics of Normandy (France), all patients aged over 50 year-old are systematically questioned about anxiety, depression, sleep quality and alcohol use disorder. They also perform a neuropsychological assessment. Questionnaires are given to the patient and his/her caregiver to be filled in at home.
Levels of anxiety/depression, sleep quality and alcohol consumption are related to neuropsychological performance, diagnosis and responses to the questionaires.
|Condition or disease|
|Anxiety State Sleep Disturbance Alcohol Abuse Aging Dementia|
|Study Type :||Observational|
|Estimated Enrollment :||3000 participants|
|Official Title:||Prevalence of Anxiety/Depression, Sleep Disturbances and Alcohol Use Disorder in Elderly With Cognitive Complaints|
|Estimated Study Start Date :||October 1, 2020|
|Estimated Primary Completion Date :||May 31, 2022|
|Estimated Study Completion Date :||May 31, 2022|
- Anxiety and depression [ Time Frame: At inclusion ]Responses to questions during anamnesis
- Sleep quality [ Time Frame: At inclusion ]Responses to questions during anamnesis
- Alcohol use disorder [ Time Frame: At inclusion ]Responses to questions during anamnesis
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04368416
|Contact: Pierre BRANGER, MDfirstname.lastname@example.org|
|Contact: Anne Lise PITEL, PhDemail@example.com|
|Principal Investigator:||Pierre BRANGER, MD||CHU CAEN|